News Releases

The information in press releases posted on the Heat Biologics website were factually accurate on the date of publication. These press releases remain on our site for historical purposes only. Heat Biologics assumes no duty to update the information to reflect subsequent developments or updates. Readers should not rely upon the information in these pages as most-current or accurate after their publication dates.

 

News Releases

Heat Biologics to Present at the 2018 BIO International Convention

Download as PDF DURHAM, NC – May 30, 2018 Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, today announced its Chief Executive Officer, Jeff Wolf, will present a...

Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering

Download as PDF DURHAM, NC – May 7, 2018 Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, today announced the closing of its previously announced underwritten...

Heat Biologics, Inc. Prices $18,000,000 Public Offering

Download as PDF DURHAM, NC – May 2, 2018 Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, today announced the pricing of an underwritten public offering with gross...

Heat Biologics Adopts Stockholder Rights Plan

Download as PDF DURHAM, NC – March 12, 2018 Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that its Board of Directors unanimously adopted a...

Heat Biologics Reports Fiscal Year 2017 Financial Results

Download as PDF DURHAM, NC – February 28, 2018 Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported financial results for the fiscal year ended December 31,...

Heat Biologics Announces Reverse Stock Split

DURHAM, NC – January 19, 2018 – Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, has announced a reverse stock split of its shares of common stock at a ratio of...

Heat Biologics Prices 5,813,950 Shares for Common Stock Offering

DURHAM, NC / ACCESSWIRE / November 17, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the pricing of an underwritten public offering of...

Heat Biologics Announces Proposed Public Offering of Common Stock

DURHAM, NC / ACCESSWIRE / November 16, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that it intends to offer for sale shares of its...

Heat Biologics Reports Third-quarter 2017 Results and Corporate Update

DURHAM, NC / ACCESSWIRE / November 13, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, reported financial and clinical updates for the third quarter ended...

Heat Biologics Announces Expected Calendar for Rights Offering

DURHAM, NC / ACCESSWIRE / September 28, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, has filed a registration statement on Form S-1 with the U.S....

Heat Biologics Inc. Reports Second Quarter 2017 Results

DURHAM, NC / ACCESSWIRE / August 14, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company focused on developing immuno-oncology therapies to activate a patient's immune response against cancer, reported financial and clinical updates for...

Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, has named Dr. Jeff Hutchins as its Chief Scientific and Operating...

Heat Biologics to Present at the 2017 BIO International Convention

DURHAM, NC / ACCESSWIRE / June 12, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, announced that CEO, Jeff Wolf, will present at the 2017 BIO...

Heat Biologics to Present at the 2017 Marcum Microcap Conference

DURHAM, NC / ACCESSWIRE / June 7, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, today announced that Jeff Wolf, Heat's CEO, will be presenting at...

Heat Biologics to Present Poster at 2017 ASCO Annual Meeting

DURHAM, NC / ACCESSWIRE / May 30, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, announced today that it will present a poster from the Phase II trial...

Heat Biologics Reports Fiscal Year 2016 Financial Results

DURHAM, N.C., March 31, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, reported financial results for the fiscal year ended December...

Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock

DURHAM, N.C., March 23, 2017 (GLOBE NEWSWIRE) -- HEAT BIOLOGICS, INC. (“HEAT”)(NASDAQ:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced the pricing of an underwritten public offering of...

Heat Biologics Announces Proposed Public Offering of Common Stock

DURHAM, N.C., March 22, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that it intends to offer for sale shares of its common...

Heat Biologics to Present at 29th Annual ROTH Conference

DURHAM, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Founder and Chief Executive...

Heat Biologics Announces Agreement to Acquire Pelican Therapeutics

Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial DURHAM, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system...

Heat Biologics to Present at the Genitourinary Cancers Symposium

DURHAM, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that it will present a poster reporting additional...

Heat Biologics to Present at NobleCon13

DURHAM, N.C., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will...

Heat Biologics to Present at Two Upcoming Investor Conferences

DURHAM, N.C., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company is scheduled to present at the...

Heat Biologics Announces Proposed Public Offering of Common Stock

DURHAM, N.C., July 21, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced today that it has commenced an underwritten public...

Heat Biologics Reports First Quarter 2016 Financial Results

DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, reported its financial results for the first quarter ended March...

Heat Biologics Appoints Dr. John Prendergast to Board of Directors

DURHAM, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company has appointed John Prendergast,...

Heat Biologics Announces Closing of Public Offering

DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced the closing of its previously announced underwritten...

Heat Biologics Announces Public Offering of Common Stock and Warrants

DURHAM, N.C., March 18, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that it has priced an underwritten public offering of...

Heat Biologics to Present at the 28th Annual ROTH Conference

DURHAM, N.C., March 04, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company is scheduled to present at the...

Heat Biologics Reports Fiscal Year 2015 Financial Results

Phase 2 Topline Data Expected in the Fourth Quarter of 2016 Evaluating HS-410 in Combination With BCG DURHAM, N.C., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a...

FDA Lifts Heat Biologics Partial Clinical Hold

Heat to Resume Patient Enrollment in Its Phase 2 HS-410 Monotherapy Arm DURHAM, N.C., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against...

Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial

The company anticipates clinical timelines for HS-410 to remain materially unchanged DURHAM, N.C., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune...

Heat Biologics to Present at Biotech Showcase 2016

DURHAM, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will...

Heat Biologics Appoints Timothy Creech as Chief Financial Officer

DURHAM, N.C., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced the appointment of Timothy Creech as Heat's new Chief...

Heat Biologics Releases Third Quarter 2015 Financial Results

DURHAM, N.C., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies to activate a patient's immune system against cancer, released its financial results for the third quarter ended...

Heat Biologics, Inc. to Present at the Marcum Microcap Conference

DURHAM, N.C., May 21, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat" or the "Company") (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate...

Heat Biologics, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., March 10, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat" or the "Company") (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that it intends to offer for sale shares of...

Heat Biologics Provides Update at Key Opinion Leader Event

-Adding Monotherapy HS-410 Arm to Current Phase 2 Bladder Cancer Study -Agreement With Society of Urologic Oncology Clinical Trials Consortium DURHAM, N.C., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical...

Heat Biologics, Inc. to Present at the BIO CEO & Investor Conference

DURHAM, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the BIO...

Heat Biologics, Inc. Outlines 2015 Corporate Objectives

- Significant Clinical Progress Anticipated with Two Lead Immunotherapy Programs - - Company also Expects to Announce New Product Development Initiatives Based on ImPACTTechnology Platform - DURHAM, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Heat Biologics,...

Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results

Company Achieves Two Key Development Milestones With Start of Patient Dosing in Phase 2 Bladder and Lung Cancer Clinical Studies DURHAM, N.C., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical stage biopharmaceutical company...

Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results

Recent Key Clinical Development Strategy Advancement Accelerates Timeline to Data Readout for Phase 1/2 Bladder Cancer Study DURHAM, N.C., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company") (Nasdaq:HTBX), a clinical...

Heat Biologics, Inc. Reports 2014 First Quarter Financial Results

Lead Immunotherapy Vaccine Product Candidates HS-110 Phase 2 Lung Cancer and HS-410 Phase 1/2 Bladder Cancer Clinical Programs Advancing Through the Clinic DURHAM, NC -- (Marketwired) -- 05/13/14 -- Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company")...

Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research

CHAPEL HILL, NC -- (Marketwired) -- 04/09/14 -- Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company") (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company...

Heat Biologics, Inc. to Present at Biotech Showcase 2014

Live Webcast of Heat's Presentation on January 14, 2014 at 10:30 a.m. PT CHAPEL HILL, NC -- (Marketwired) -- 01/07/14 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies,...

Heat Biologics, Inc. to Present at 12th Annual BIO Investor Forum

CHAPEL HILL, NC -- (Marketwired) -- 10/02/13 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will...

Heat Biologics Files IND for Bladder Cancer Product Candidate

Appoints Dr. Melissa Price as Vice President, Clinical and Regulatory Affairs CHAPEL HILL, NC -- (Marketwired) -- 10/01/13 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies,...

Heat Biologics Appoints Louis C. Bock to Board of Directors

CHAPEL HILL, NC -- (Marketwired) -- 09/25/13 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that it has appointed industry veteran Louis C. Bock to its...